GlassScriptPhysician profile
Shakedia Pope
NPI 1427600642
$4,968.38
in general payments reported to CMS, 2019-2025
27 companies · $734 in 2025
The $734 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,132 · 2022: $1,188 · 2023: $999 · 2024: $915 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,627.79 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $1,165.52 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $292.24 | 2021-2025 | |
| Galderma Laboratories, L.P. | $190.06 | 2024-2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $184.92 | 2021-2025 | Trintellix |
| Amgen INC. | $159.00 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $158.41 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $141.89 | 2021-2023 | Shingrix, Boostrix |
| Medtronic, INC. | $131.77 | 2022 | |
| Pfizer INC. | $127.18 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.25 | 2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $97.62 | 2022 | |
| Currax Pharmaceuticals LLC | $93.96 | 2021-2025 | Contrave |
| Merz North America, INC. | $92.42 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $53.70 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.86 | 2021-2022 | |
| Dexcom, INC. | $35.85 | 2021-2022 | |
| Corcept Therapeutics | $34.13 | 2021-2023 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $30.53 | 2022 | |
| Edwards Lifesciences Corporation | $28.90 | 2022 | |
| Endo Pharmaceuticals INC. | $27.56 | 2021 | |
| Boston Scientific Corporation | $27.50 | 2022-2023 | Watchman |
| Amarin Pharma, INC. | $23.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2021 | |
| Vivus LLC | $20.74 | 2023 | Qsymia |
| Nestle Healthcare Nutrition INC. | $19.22 | 2021 | |
| Revance Therapeutics, INC. | $13.65 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakedia Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.